The Company is actively pursuing the application of the Coferon platform in the area of epigenetics where we believe that the modular, combinatorial and selective intracellular targeting capabilities of the platform, combined with the equally modular regulatory biology of Protein Interaction Domains (PID’s) can lead to a rapid and synergistically efficient demonstration of the platforms application in drug discovery programs. We believe that the ability to deliver a large molecule binding footprint to these intracellular protein:protein interaction targets – which have proven challenging to address with classic small molecule approaches – will allow us to tease out important potency and selectivity advantages for Coferon based drugs.

Source: Pawson Lab, MSHRI

Closely related families of epigenetic regulatory binding domains such as the BRD family are attractive targets in this regard.  Therapeutics targeting the BRD family, most notably BRD4, are being actively pursued by many companies with classic small molecule approaches.  The BRD4, BRD2, BRD-T and the BRD4-NUT and BRD3-NUT oncogenic fusion proteins all offer intriguing targets for therapeutic intervention with potent and selective coferon-based therapeutics and are an initial focus of the Coferon epigenetic discovery program.